Finerenone in patients with chronic kidney disease and type 2 diabetes with and without heart failure: a prespecified subgroup analysis of the FIDELIO‐DKD trial
Sign Up to like & getrecommendations! Published in 2022 at "European Journal of Heart Failure"
DOI: 10.1002/ejhf.2469
Abstract: This prespecified analysis of the FIDELIO‐DKD trial compared the effects of finerenone, a selective non‐steroidal mineralocorticoid receptor antagonist, on cardiorenal outcomes in patients with chronic kidney disease (CKD) and type 2 diabetes (T2D) by history… read more here.
Keywords: heart failure; dkd trial; analysis fidelio; fidelio dkd ... See more keywords
Finerenone Dose–Exposure–Serum Potassium Response Analysis of FIDELIO-DKD Phase III: The Role of Dosing, Titration, and Inclusion Criteria
Sign Up to like & getrecommendations! Published in 2021 at "Clinical Pharmacokinetics"
DOI: 10.1007/s40262-021-01083-1
Abstract: Finerenone is a nonsteroidal selective mineralocorticoid receptor antagonist (MRA) that demonstrated efficacy in delaying the progression of chronic kidney disease (CKD) and reducing cardiovascular events in patients with CKD and type 2 diabetes mellitus in… read more here.
Keywords: potassium; response; finerenone dose; fidelio dkd ... See more keywords